Does Additional Resection of a Positive Microscopic Ductal Margin Benefit Patients with Perihilar Cholangiocarcinoma: A Systematic Review and Meta-analysis
Overview
Affiliations
Background: The incidence of a positive microscopic ductal margin (R1) after surgical resection for perihilar cholangiocarcinoma (pCCA) remains high, but the beneficial of additional resection has not been confirmed by any meta-analysis and randomized clinical trials (RCT), which also increased the risk of morbidity and mortality. Hence, a systematic review is warranted to evaluate the clinical value of additional resection of intraoperative R1 for pCCA.
Methods: Eligible studies were searched by PubMed, MedLine, Embase, the Cochrane Library, Web of Science, from Jan.1st 2000 to Nov.30th 2019, evaluating the 1-, 3-, and 5-year overall survival (OS) rates of additional resection of intraoperative pathologic R1 for pCCA. Odds ratio (OR) with 95% confidence interval (CI) was used to determine the effect size by a randomized-effect model.
Results: Eight studies were enrolled in this meta-analysis, including 179 patients in the secondary R0 group, 843 patients in the primary R0 group and 253 patients in the R1 group. The pooled OR for the 1-, 3-, and 5-year OS rate between secondary R0 group and primary R0 group were 1.03(95%CI 0.64~1.67, P = 0.90), 0.92(95%CI 0.52~1.64, P = 0.78), and 0.83(95%CI 0.37~1.84, P = 0.65), respectively. The pooled OR for the 1-, 3-, and 5-year OS rate between secondary R0 group and R1 group were 2.14(95%CI 1.31~3.50, P = 0.002), 2.58(95%CI 1.28~5.21, P = 0.008), and 3.54(95%CI 1.67~7.50, P = 0.001), respectively. However, subgroup analysis of the West showed that the pooled OR for the 1-, and 3-year OS rate between secondary R0 group and R1 group were 2.05(95%CI 0.95~4.41, P = 0.07), 1.91(95%CI 0.96~3.81, P = 0.07), respectively.
Conclusion: With the current data, additional resection should be recommended in selected patients with intraoperative R1, but the conclusion is needed further validation.
Varty G, Goel M, Nandy K, Deodhar K, Shah T, Patkar S Indian J Surg Oncol. 2024; 15(Suppl 2):281-288.
PMID: 38818011 PMC: 11133294. DOI: 10.1007/s13193-024-01874-5.
Surgical management of hilar cholangiocarcinoma: Controversies and recommendations.
Jena S, Mehta N, Nundy S Ann Hepatobiliary Pancreat Surg. 2023; 27(3):227-240.
PMID: 37408334 PMC: 10472117. DOI: 10.14701/ahbps.23-028.
Lenet T, Gilbert R, Smoot R, Tzeng C, Rocha F, Yohanathan L Ann Surg Oncol. 2022; 29(12):7592-7602.
PMID: 35752725 DOI: 10.1245/s10434-022-12041-x.
Impact of Positive Radial Margin on Recurrence and Survival in Perihilar Cholangiocarcinoma.
DAmico F, Mescoli C, Caregari S, Pasquale A, Billato I, Alessandris R Cancers (Basel). 2022; 14(7).
PMID: 35406452 PMC: 8996964. DOI: 10.3390/cancers14071680.
Surgical Therapy for Perihilar Cholangiocarcinoma: State of the Art.
Nooijen L, Swijnenburg R, Klumpen H, Verheij J, Kazemier G, van Gulik T Visc Med. 2021; 37(1):18-25.
PMID: 33708815 PMC: 7923954. DOI: 10.1159/000514032.